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Abstract
Chromosomal translocations are rare in myelodysplastic syndrome (MDS) and their impact
on overall survival (OS) and response to hypomethylating agents (HMA) is unknown. The
prognostic impact of the revised International Prognostic Scoring System (IPSS-R) and for
chromosomal translocations was assessed in 751 patients from the Korea MDS Registry.
IPSS-R effectively discriminated patients according to leukaemia evolution risk and OS.
We identified 40 patients (5.3%) carrying translocations, 30 (75%) of whom also fulfilled
complex karyotype criteria. Translocation presence was associated with a shorter OS
(median, 12.0 versus 79.7 months, P < 0.01). Multivariate analysis demonstrated that
translocations (hazard ratio [HR] 1.64 [1.06–2.63]; P = 0.03) as well as age, sex, IPSS-R,
and CK were independent predictors of OS. In the IPSS-R high and very high risk subgroup
(n = 260), translocations remained independently associated with OS (HR 1.68 [1.06–
2.69], P = 0.03) whereas HMA treatment was not associated with improved survival
(median OS, 20.9 versus 21.2 months, P = 0.43). However, translocation carriers exhibited
enhanced survival following HMA treatment (median 2.1 versus 12.4 months, P = 0.03).
Our data suggest that chromosomal translocation is an independent predictor of adverse
outcome and has an additional prognostic value in discriminating patients with MDS having
higher risk IPSS-R who could benefit from HMA treatment.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid disorders
characterized by ineffective haematopoiesis resulting in bone marrow (BM) failure and
increased risk of transformation to acute myeloid leukaemia (AML) [1]. Chromosomal translo-
cations are rare in MDS, whereas other chromosomal abnormalities such as losses and gains of
genetic material are detected in half of all patients with MDS. The International Prognostic
Scoring System (IPSS) [2] and revised IPSS (IPSS-R) [3] comprise the most accepted prognos-
tic scoring systems incorporating 3 and 5 cytogenetic prognostic subgroups, respectively, yet
chromosomal translocations other than t(3q) are not considered in the cytogenetic classifica-
tion. Owing to recent advances in technologies such as whole genome sequencing, recurrent
mutations in splicing factor (e.g., SF3B1 and U2AF1) and epigenetic regulator (e.g.,TET2,
ASXL2,DNMT3A, EZH2, and IDH1/2) genes have been identified as the predominant molecu-
lar mechanism underlying the pathogenesis of MDS [4–6]. However, since the identification
and reporting of recurrent chromosomal translocations are essential to provide insights into
the mechanisms of pathogenesis and identify genes involved in the pathogenesis of MDS, the
role of cytogenetics including the study of genomic structure and functionwill remain impor-
tant. Novel and recurrent translocations have been reported in a large series of patients [7,8];
however, only a few studies have addressed the prognostic impact of chromosomal transloca-
tions [9–11].
Accordingly, the aims of this study were: (1) to validate the prognostic power of IPSS-R in a
large cohort of adults with primaryMDS and (2) to assess the incidence, characteristics, and
potential prognostic impact of chromosomal translocation in this cohort.
Patients and Methods
Study population
The Korea MDS registrywhich is sponsored by the Korean Society of Haematology holds data
frommajor centres in Korea that treated patients withMDS between January 2004 and Decem-
ber 2011. We conducted a retrospective study of these data, resulting in the enrolment of a
total of 751 consecutive patients for whom the complete data set needed to calculate the IPSS
or IPSS-R score. We excluded patients with secondaryMDS, chronic myelomonocytic leuke-
mia (CMML), and patients with AML and a BM blast count of 20–30% who were classified as
having refractory anaemia with excess blast (RAEB)-t according to the French-American-Brit-
ish classification [12]. Patients were then reclassified according to the 2008 WHO criteria [13].
The individual review boards of all participating institutions approved this study, and it was
conducted in accordance with the Declaration of Helsinki.
Cytogenetic analyses
Cytogenetics was evaluated using BM cells with standard banding techniques and the cytogenetic
abnormalities were classified according to the International System for Human Cytogenetic
Nomenclature criteria [14]. At least 20 metaphases per sample were analysed when possible and
the cytogenetic reports were centrally reviewed.Aberrations were counted following the Interna-
tionalWorking Group onMDS Cytogenetics (IWGMC) consensus guidelines [15]. Patients with
3 or more choromosmal abnormalities were defined having complex karyotype (CK).Monoso-
mal karyotype (MK) was defined as the presence of at least 2 autosomal monosomies or 1 single
autosomal monosomy in combination with structural abnormalities. The Atlas of Genetics and
Cytogenetics in Oncology and Haematology [http://atlasgeneticsoncology.org] was reviewed to
determinewhether the translocations in our study population had been previously reported.
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Statistical analysis
Patient characteristics between groups were compared using the χ2-test, Fisher’s exact test, or
MannWhitney U-test as appropriate. Overall survival (OS) was defined as the duration of time
between the date of first diagnosis and the date of last follow-up or death from any cause. The
period of leukaemia-free survival (LFS) was defined as the duration of time between the date of
diagnosis to the date of AML evolution or death from any cause, whichever came first. OS and
LFS were estimated using the Kaplan-Meier method and the values were compared by the log-
rank test. Univariate Cox proportional-hazard regression (PHR) analyses were performed to
evaluate the prognostic values of each variable and variables found to be significant on univari-
ate analysis were introduced into a multi-variable Cox PHRmodel for LFS and OS. All tests
were two-sided, and a P value of less than 0.05 indicated a statistically significant difference. All
analyses were performed using SPSS Version 22.0 (SPSS; Chicago, IL, USA) and GraphPad
Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) on data collected through December
2015.
Results
Patient characteristics
The clinical characteristics of 751 patients are shown in Table 1. The median age of the patients
was 65 years, and 457 (61.9%) were male. The median follow-up time was 98.5 months (range,
38.1–246.6). The most commonWHO subtype was refractory cytopaenia with multilineage
dysplasia (29.7%), followed by RAEB-1 (19.8%), RAEB-2 (18.4%), refractory cytopaenia with
unilineage dysplasia (15.4%), and MDS-unclassifiable (11.9%). More than half of patients
received disease-modifyingtreatment; 381 (50.7%) received hypomethylating agents (HMAs),
and 83 (11.1%) received haematopoietic stem cell transplantation (HSCT).
Analysis of IPSS and IPSS-R
We calculated the IPSS and IPSS-R scores at diagnosis. According to the IPSS classification,
140 (18.6%) patients were considered to be low-risk, 419 (55.8%) intermediate-1 risk, 150
(20.0%) intermediate-2 risk, and 42 (5.6%) high-risk. The OS among these 4 groups were sig-
nificantly different (not reached [NR], 73.0, 21.0, and 12.9 months for IPSS low, intermediate-
1, intermediate-2, and high risk, respectively;P< 0.01) (Fig 1A). There was also a statistically
significant difference in LFS among these 4 groups (P< 0.01, Fig 1C). However, we could not
identify an intergroup difference in LFS between the intermediate-2 and high risk groups
(P = 0.08). According to the IPSS-R, 51 patients (6.8%) were considered to be very low-risk,
221 (29.4%) low-risk, 219 (29.2) intermediate-risk, 152 (20.2%) high-risk, and 108 (14.4%)
very high-risk. For these groups, the median survivals were NR, NR, 68.2, 25.9, and 13.5
months, respectively (P< 0.01) (Fig 1B). However, we could not identify an intergroup differ-
ence in OS between the very low and low risk groups (P = 0.07). IPSS-R was able to stratify
patients with respect to LFS (P< 0.01, Fig 1D).
Chromosomal translocation in patients with MDS
A total of 291 patients (38.7%) demonstrated an abnormal karyotype, of whom 40 had chro-
mosomal translocations, representing 5.3% of all patients and 13.7% of patients with abnormal
karyotype. Among these, 46 translocations involving 72 breakpoints were identified including
balanced translocations in 13 (28.3%) and unbalanced in 33 (71.7%). CK and MK were found
in 91 and 73 patients representing 31.3% and 25.1% of patients with an abnormal karyotype,
respectively. Translocations were found as a part of CK in 30/46 (65.2%) cases and as a part of
IPSS-R and Chromosomal Translocations in Korean MDS Patients
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MK in 21/46 (45.7%). Table 2 illustrates the details of the patients with chromosomal translo-
cations including diagnosis, treatment, and duration of survival. All chromosomes except for
chromosome 18 and the Y chromosome participated in the translocations. Frequently involved
chromosomes were chromosome 7 (n = 13); ch1 (n = 12); ch5 (n = 9); ch12 (n = 6); ch6, ch11,
and ch14 (n = 5); ch10 and ch20 (n = 4); and ch16, ch17, and X (n = 3) in decreasing order. To
the best of our knowledge, 43 (93.5%) of the 46 translocations have not been previously
described in MDS, nor in AML or CMML. All translocations involved breakpoints recurrently
involved in translocations with other partners in MDS, CMML, and AML. Some of the break-
points (29/72, 40.3%) included genes related to MDS or AML (Table 2). Patients with chromo-
somal translocation exhibited worse prognostic baseline characteristics compared with those
without translocation (Table 1). Patients with translocation also had a higher percentage of BM
blasts and included a significantly larger proportion of RAEB-1 and RAEB-2. The raw number
Table 1. Baseline Characteristics of 751 patients with MDS.
Variables n Translocation (n = 40) No translocation (n = 711) P-value
Age (years) <60 286 10 (25.0) 276 (38.8) 0.08
60 465 30 (75.0) 435 (61.2)
Gender Male 457 23 (57.5) 434 (61.0) 0.66
Female 294 17 (42.5) 277 (39.0)
ANC (x 109/L) (median, range) 0.86 (0.67–6.99) 1.20 (0–52.99) 0.36
Hb (g/dL) (median, range) 8.1 (4.4–14.5) 8.5 (2.8–15.9) 0.30
Platelets (x 1012/L) (median, range) 72 (6–288) 76 (1–4120) 0.33
BM blasts (%) (median, range) 5.4 (0–19.8) 2.5 (0–20) <0.01
Diagnosis RARS 28 0 28 (4.0) <0.01
RCUD 115 2 (5.0) 113 (16.0)
RCMD 223 9 (22.5) 214 (30.3)
RAEB-1 149 9 (22.5) 140 (19.8)
RAEB-2 138 18 (45.0) 120 (17.0)
MDS-U 89 2 (5.0) 87 (12.3)
Del5q 5 0 5 (0.7)
Unknown 4 0 4 (0.6)
IPSS Low 140 0 140 (19.7) <0.01
Int-1 419 7 (17.5) 412 (57.9)
Int-2 150 20 (50) 130(18.3)
High 42 13 (32.5) 29 (4.1)
IPSS-R Very low 51 0 51 (7.2) <0.01
Low 221 1 (2.5) 220 (30.9)
Intermediate 219 4 (10.0) 215 (30.2)
High 152 9 (22.5) 143 (20.1)
Very high 108 26 (65.0) 82 (11.5)
HMA Yes 381 27 (67.5) 354 (49.8) 0.03
No 370 13 (32.5) 347 (50.2)
HSCT Yes 83 3 (7.5) 80 (11.3) 0.46
No 668 37 (92.5) 631 (88.7)
Abbreviations: MDS, myelodysplastic syndrome; ANC, absolute neutrophil count; Hb, hemoglobin; BM, bone marrow; WHO, World Health Organization;
RARS, refractory anemia with ringed sideroblasts; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage
dysplasia; RAEB, refractory anemia with excess blast; MDS-U, MDS unclassified; IPSS, International Prognostic Scoring System; IPSS-R, Revised IPSS;
HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation.
doi:10.1371/journal.pone.0166245.t001
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of chromosomal aberrations were higher in the patients with translocation compared with
those without in all patients (median number of aberration 1.0 [range, 0–16.0] versus 5.5 [1.0–
22.0], P< 0.01); identical results were obtained when the analysis was restricted to the patients
with any chromosomal aberration (2.0 [1.0–16.0] versus 5.5 [1.0–22.0], P< 0.01).
Effect of chromosomal translocation on outcome
Patients with chromosomal translocation had markedly inferior OS in comparison with the
rest of the patient cohort (median OS, 12.0 versus 79.7 months, P< 0.01) (Fig 2A). Patients
with MK or CK also exhibited worse survival than those without (median OS, 12.8 versus 100.6
months, P< 0.01 and 12.8 versus 111.0 months, P< 0.01, respectively). Among patients with
CK, the presence of MK did not have an impact on either OS or LFS (median OS, 9.9 months
for MK versus 17.3 months for non-MK, P = 0.21 and median LFS 8.5 months for MK versus
14.1 for non-MK, P = 0.23, respectively) (S1 Fig). In contrast, presence of a chromosomal
translocation was sufficient to stratify the CK group; patients with translocation had distinctly
poorer OS and LFS than those without (median 8.2 versus 16.6 months, P< 0.01 and median
7.2 versus 12.8 months, P< 0.01, respectively) (Fig 2B). Among 106 patients with very poor
Fig 1. Kaplan-Meier survival curves of overall survival (A and B) and leukemia-free survival (C and D) in 751 patients with primary MDS stratified by IPSS
and IPSS-R.
doi:10.1371/journal.pone.0166245.g001
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Table 2. Balanced and Unbalanced Translocations in MDS patients.
No. Age/
Sex
Translocation Karyotype Diagnosis Translocation reported Genes (breakpoints) IPSS-R Tx AL OS (mo)
1 64/M der(7)t(1;7)(q21;q11.2) CK RAEB-2 1q21b,c / 7q11a HIP1 (7q11) VH HMA No 0.6
(Died)
2 67/M der(20)t(12;20)(q13;q13.3) CK, MK RCMD 12q13b,c / 20q13b,c NCOA3 (20q13) VH HMA No 1.5
(Died)
3 65/M der(3)t(3;7)(p14;p13) CK, MK RAEB-1 3p14a / 7p13a,c - VH HMA No 8.2
(Died)
4 86/F t(4;16;12)(q25;p13.3;q13) AA RAEB-1 4q25b / 16p13b / 12q13b,c CREBBP, GLIS2, MYH11
(16p13)
I BSC No 58.7
(Alive)
5 42/F der(5)t(5;11)(q22;q13) CK RAEB-1 5q22b,c / 11q13b MACROD1, NUMA1 (11q13) VH HMA Yes 13.3
(Died)
6 75/M der(14;20)t(14;20)(q10;p10) CK, MK RAEB-1 14q10b / 20p10a - VH BSC No 2.1
(Died)
7 60/F der(1)t(1;7)(q10;p10) MK MDS-U 1q10b / 7p10b,c - I HSCT No 20.3
(Died)
8 64/M t(3;?)(q21;?) CK, MK RAEB-2 3q21b GATA2, RPN1 (3q21) VH HMA No 1.0
(Died)
9 78/F der(12)t(12;14)(p13;q11.2) CK, MK RCMD 12p13b / 14q11a,c ETV6, KDM5A, ZNF384
(12p13)
VH BSC No 0.2
(Died)
10 74/F der(11)t(11;11)(q23;p15) CK RAEB-2 11p15b / 11q23b NUP98 (11p15), MLL
(11q23)
VH HMA Yes 12.6
(Died)
11 66/M der(5)t(X;5)(q22;q13) CK RAEB-1 Xq22a / 5q13b,c - VH BSC No 0.5
(Died)
12 83/M der(5)t(5;7)(q22;p13) CK, MK RCMD 5q2b / 7p13a,c - VH HMA No 12.2
(Loss)
13 65/M t(7;10)(q10;p10) CK, MK RAEB-2 7q10b / 10p10a - VH HMA No 14.1
(Died)
14 77/F der(7)t(1;7)(p22;p10), der(17)t
(8;17)(q13;p12)
CK, MK RAEB-2 1p22b,c / 7p10b,c / 8q13a /
17p12b
CLCA2 (1p22), NCOA2
(8q13)
VH HMA Yes 12.5
(Loss)
15 68/M t(17;21)(q21;q22) AA RCMD Acute leukemia H HMA No 31.8
(Died)
16 76/M der(16)t(7;16)(p15;p13.1), t(1;6)
(p31;q21), t(12;15)(q13;q11.2)
CK, MK RAEB-2 7p15b / 16p13b / 1p31a /
6q21b / 12q13b,c / 15q11a,c
HOXA9 (7p15), FOXO3
(6q21)
VH HMA Yes 13.5
(Died)
17 72/M der(22)t(22;?)(q10;?) CK, MK RCMD 22q10a - VH BSC No 2.4
(Died)
18 60/F der(16)t(16;17)(q13;q11.2) CK, MK RAEB-2 16q13b / 17q11a KSR1, WSB1, MYO18A,
GOSR1, ZNF207, NF1
(17q11)
VH HMA Yes 23.4
(Died)
19 31/F der(8)t(8;20)(q10;q12) CK RCUD 8q10b / 20q12b TOP1 (20q12) H BSC No 12.9
(Loss)
20 42/M der(6)t(1;6)(q21;p23) AA RAEB-1 1q21b,c / 6p23b,c - H HMA No 2.3
(Died)
21 60/M der(5)t(5;15)(q13;q11.2) CK, MK RCMD 5q13b,c / 15q11a,c - H HMA No 9.9
(Died)
22 52/M der(7)t(1;7)(q12q36) AA RAEB-2 7q36b EZH2, MNX1 (7q36) VH HMA Yes 6.5
(Died)
23 71/M t(1;7)(p22;q32) CK, MK RAEB-1 1p22b,c / 7q32b - VH HMA No 1.1
(Died)
24 60/M der(2)t(2;10)(p?25;q?22), der(5)t
(5;14)(q22;q11.2), der(6)t(6;10)
(p23;q22)
CK, MK RCMD 2p25a / 10q22b,c / 5q22b,c /
14q11a,c / 6p23b,c
KAT6B, KCNMA1 (10q22) VH HMA No 1.5
(Died)
25 56/M t(5;7)(q13;q22) CK RAEB-2 5q13b,c / 7q22b ZNF789, ZNF394 (7q22) H HMA No 57.2
(Loss)
26 67/F der(17)t(12;17)(q12;p11.2) CK, MK RAEB-2 12q12a / 17p11b CPNE8 (12q12), SPECC1
(17p11)
VH HMA No 33.7
(Loss)
27 34/F der(7)t(6;7)(p21;p22) CK, MK RAEB-2 AML VH HSCT Yes 13.4
(Died)
28 63/F t(1;14)(p36.1;q24) CK RAEB-2 1p36b /14q24a CDK11B, PRDM16, MTOR
(1p36)
VH HMA No 12.4
(Died)
(Continued)
IPSS-R and Chromosomal Translocations in Korean MDS Patients
PLOS ONE | DOI:10.1371/journal.pone.0166245 November 8, 2016 6 / 17
and poor karyotype, 31 carried translocations. The presence of a translocation also adversely
affected survival (Fig 2C).
Of the 40 patients with translocations, 13 had translocation involving chromosome 7.
Patients with chromosome 7 translocation had similar OS and LFS compared with the patients
with translocation involving other chromosomes (P = 0.72 and P = 0.63, respectively). Clinical
outcome of patients with chromosome 7 translocation was also compared with those of
patients with monosmy 7. Seven patients had translocation involving chromosome 7, twenty-
four patients had monosomy 7, and six patients had both abnormalities. OS did not differ sig-
nificantly according to the type of abnormality involving chromosome 7 (median OS 12.0
months for chromosome 7 translocation vs. 8.5 months for monosomy 7 vs. 14.1 months for
both abnormalities, P = 0.62).
Of the 40 patients with translocations, 7 had translocation involving 5q, which has been sug-
gested as a poor prognostic cytogenetics [16]. After excluding 7 patients with t(5q), patients
with translocation still had markedly inferior OS and LFS in comparison with the rest of the
patient cohort (median OS, 12.4 versus 75.3 months, P< 0.01; median LFS, 7.4 versus 55.3
months, P< 0.01) (S2 Fig).
Table 2. (Continued)
No. Age/
Sex
Translocation Karyotype Diagnosis Translocation reported Genes (breakpoints) IPSS-R Tx AL OS (mo)
29 57/F der(16)t(1;16)(q21;q22) A MDS-U 1q21b,c /16q22b CBFB, NFATC3, PLA2G15
(16q22)
I BSC No 96.7
(Alive)
30 77/F der(12)t(7;12)(p11.2;p11.2) CK, MK RAEB-2 7p11b / 12p11b FGFR1OP2 (12p11) VH HMA No 5.0
(Loss)
31 56/M der(6)t(6;13)(p12;q22) CK, MK RAEB-2 6p12a / 13q22b CLN5, FBXL3 (13q12) VH HMA Yes 6.8
(Died)
32 35/F t(1:19)(q21:q13) CK RCMD 1q21b,c /19q13b CEBPA (19q13) H BSC No 0.9
(Died)
33 64/F t(9;22)(q34;q11.2) CK RAEB-2 AML, RAEB-2 VH HMA No 7.2
(Died)
34 65/M der(1)t(1;10)(p13;q24) A RAEB-1 1p13b / 10q24a NRAS, RBM15, DDX20
(1p13), GOT1, NT5C2
(10q24)
H HMA No 21.0
(Died)
35 65/F del(20)t(1;20)(q11;q13.3) A RCUD 1q11b / 20q13b,c NCOA3 (20q13) I BSC No 7.1
(Died)
36 67/M del(13)t(5;13)(q21;q14),der(7)t(5;7)
(p14;p13)
CK, MK RAEB-2 5q21b / 13q1b, 5p14a /
7p13a,c
- H HMA No 12.0
(Died)
37 76/F t(X;11)(q13;q25) CK, MK RAEB-1 Xq13b/ 11q25b FOXO4 (Xq13) VH HMA Yes 4.0
(Died)
38 70/M t(4;14)(q35;q22) A RCMD 4q35a / 14q22b - L BSC No 88.5
(Alive)
39 79/M t(11;21)(p13;q21) CK, MK RAEB-2 21q22b RUNX1 (21q22) VH BSC No 3.2
(Died)
40 58/M t(x:5)(q24;p15.3) AA RAEB-2 Xq24a / 5p15a SEPT6 (Xq24) H HMA,
HSCT
Yes 20.7
(Died)
Abbreviations: CK, complex karyotype; MK, monosomal karyotype; AA, associated with another chromosomal abnormality; A, isolated chromosomal
abnormality; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB refractory anemia with
excess blasts; MDS-U, MDS unclassified;.IPSS-R, revised International Prognostic Scoring System; Tx, treatment; HMA, hypomethylating agent; BSC,
best supportive care; HSCT, hematopoietic stem cell transplantation; AL, evaluation to acute leukemia; OS, overall survival.
aBreakpoints reported in AML.
bBreakpoints reported in both AML and MDS.
cBreakpoints reported more than 2 times in this study population.
doi:10.1371/journal.pone.0166245.t002
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Fig 2. Overall survival according to presence of chromosomal translocation in (A) the whole population, and
(B) patients with complex karyotype (CK), and (C) patients with IPSS-R poor and very poor cytogenetics.
doi:10.1371/journal.pone.0166245.g002
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Among the entire cohort of 751 patients, chromosomal translocation remained a significant
variable associated with shorter OS in multivariate analysis (HR 1.64, 95% CI 1.06–2.54,
P = 0.03). Other variables that retained statistical significance for OS were: age> 60 years (HR
1.61, 95% CI 1.21–2.15, P< 0.01), male sex (HR 1.42, 95% CI 1.10–1.84, P< 0.01), CK (HR
1.75, 95% CI 1.17–2.63, P< 0.01), and higher IPSS-R risk group (P< 0.01) (Table 3). Chromo-
somal translocation was independently associated with LFS as well with the same variables as
entered in the regression model (HR 1.56 [1.03–2.43], P = 0.04). Chromosomal translocation
remained a significant variable associated with shorter OS (HR 1.89, 95% CI 1.21–2.95,
P< 0.01) and LFS (HR 1.80, 95% CI 1.17–2.77, P< 0.01) even after excluding 7 patients with t
(5q) (S1 Table).
When the analysis was restricted to patients with chromosomal abnormalities (n = 271),
translocation was a significant predictor of poor OS and LFS (HR for OS, HR 1.856, 95% CI
1.198–2.876, P< 0.01; HR for LFS, 1.733, 95% CI 1.132–2.653, P = 0.01).
Analysis of the prognostic factors of patients with higher risk according
to the IPSS-R
Since the proportion of cases with chromosomal translocations increased as the IPSS-R scores
increased, we performed a separate analysis to evaluate the prognostic impact of translocation
in the different IPSS-R cohorts. Patients with very low, low, and intermediate risk groups were
excluded because there were only five patients with translocation in these cohorts; there were
260 patients in the IPSS-R high and very high risk group. Variables including older age at diag-
nosis, presence of chromosomal translocation,MK, CK, and IPSS-R very high risk group were
significantly associated with poorer OS and LFS. Since disease-modifyingtreatments such as
HMAs and HSCT are recommended treatment in the higher risk group, we analysed the effect
Table 3. Multivariate analyses for OS and LFS.
Variables HR for OS (95% CI) p-value HR for LFS (95% CI) P-value
Age
< 60 1 1
 60 1.61 (1.21–2.15) < 0.01 2.07 (1.61–2.67) <0.01
Sex
Female 1
Male 1.42 (1.10–1.84) < 0.01 NSS
Translocation
No 1 1
Yes 1.64 (1.06–2.54) 0.03 1.58 (1.03–2.43) 0.04
CK
No 1 1
Yes 1.75 (1.17–2.63) < 0.01 1.70 (1.10–2.63) 0.02
IPSS-R
Very Low 1 1
Low 2.82 (1.01–7.86) 0.05 2.66 (1.06–6.68) 0.04
Intermediate 6.20 (2.27–16.95) < 0.01 5.11 (2.05–12.72) <0.01
High 10.78 (3.93–29.57) < 0.01 6.26 (2.43–16.12) <0.01
Very High 12.31 (4.33–34.96) < 0.01 8.92 (3.32–23.98) <0.01
Abbreviations: HR, hazard ratio; CI, confidence interval; IPSS-R, Revised International Prognostic Scoring System; OS, overall survival; CK, complex
karyotype; NSS, not statistically significant.
doi:10.1371/journal.pone.0166245.t003
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of these treatments on OS and LFS. Among 260 patients, 40 (15.4%) receivedHSCT and 171
(65.8%) receivedHMAs; 121 received azacitidine, and 50 received decitabine, with a median of
4 cycles (range, 1–26). The median OS and LFS were significantly longer in the patients who
receivedHSCT compared to those not receivingHSCT (NR versus 17.4 months, P< 0.01 and
NR versus 13.5 months, P< 0.01, respectively). In contrast, treatment with HMAs was not
associated with statistically significant improvement in OS (median 21.0 [18.1–23.9] months
for patients treated with HMA versus 21.0 [3.8–38.7] months for the others, P = 0.50) (Fig 3A)
or LFS (median 17.8 [13.9–21.6] versus 16.2 [7.6–24.8], P = 0.35). Also, HMA treatment was
not associated with better OS when analysis was restricted to 156 patients with chromosomal
abnormality (median OS 21.0 months for both HMA treated patients and the rest, P = 0.50).
Notably, treatment with HMAs significantly improved OS in patients with translocations
(median 2.1 versus 12.4 months, P = 0.03) (Fig 3B), whereas this survival difference was not
observed for patients without translocation (30.6 months for not treated versus 23.7 months
for treated groups, P = 0.40) (Fig 3C).
The results from a multivariate analysis of these higher-risk patients, which included age,
sex,WHO subtype, MK, CK, translocation, IPSS-R, HMAs, and HSCT indicated that only
chromosomal translocation and HSCT were significantly associated with both LFS and OS
(Table 4).
BecauseHSCT significantly influenced outcome for these high risk patients, we analysed
the effect of HMA on prognosis after excluding the 40 patients who had undergone HSCT. The
results were virtually the same in the remaining 220 patients; i.e., that treatment with HMA
was associated with better outcome only in patients with chromosomal translocation (median
OS 2.1 months for patients not treated with HMA versus 12.0 months for patients treated with
HMA, P = 0.01).
Analysis of the prognostic factors in patients who received HMAs
We next investigated the association of chromosomal translocation and the clinical outcome of
patients treated with HMAs. We excluded 4 patients with an IPSS-R very low risk score. A
total of 377 patients with IPSS-R low to very high risk scores had received HMAs; 267 received
azacitidine and 110 received decitabine. The median duration of time between diagnosis and
HMA initiation was 22 days (range, 1–3128). Among the 377 patients, 27 (7.2%) had a chro-
mosomal translocation.
Response to HMAwas evaluable in 271 patients; 22 of these patients had chromosomal
translocations. Response was defined as achieving complete remission (CR), complete marrow
response (mCR), partial response (PR), and hematologic improvement (HI). Stable disease
without HI, and progressive disease (PD) were considered non-response. Response to HMAs
were associated with the presence of chromosomal abnormality (response rate [RR] 41.1% for
patients with normal karyotype vs. 27.4% for those with abnormal karyotype, P = 0.048). How-
ever, chromosomal translocation was not associated with the RR of HMAs (35.3% for patients
without translocation vs. 27.3% for those with translocation, P = 0.45) (S2 Table).
In univariate analysis, older age, translocation,MK, higher IPSS-R, and not receivingHSCT
were correlated with shorter OS. Chromosomal translocation was independently associated
with poorer OS (HR 1.71, 95% CI 1.04–2.82, P = 0.03) in multivariate analysis (Table 5). Other
variables independently associated with OS were MK (HR 1.68, 95% CI 1.09–2.60, P = 0.02),
IPSS-R (high risk: HR 0.86, 95% CI 0.57–1.31, P = 0.49; intermediate risk: HR 0.54, 95% CI
0.34–0.85, P< 0.01; low risk: HR 0.22, 95% CI (0.12–0.39), P< 0.01), and HSCT (HR 0.43,
95% CI 0.27–0.67, P< 0.01). Chromosomal translocation was also correlated with poorer LFS
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Fig 3. Impact of hypomethylating agents (HMAs) on overall survival (OS) in IPSS-R high and very
high risk group. (A) Survival curves in patients treated with HMAs or not treated with HMAs. Impact of
HMAs on OS in the subgroup of patients with chromosomal translocation (B) and without chromosomal
translocation (C).
doi:10.1371/journal.pone.0166245.g003
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in multivariate analysis with the same variables as entered in the regression model (HR 1.86,
95% CI 1.17–2.95, P< 0.01), whereasMK did not remain in the model.
Discussion
In our study of 751 MDS patients from the Korea MDS Registry, we identified chromosomal
translocation in 5.7% of our cohort of patients with MDS. Chromosomal translocation was
associated with higher BM blast percentage at diagnosis, in accordance with a higher propor-
tion of RAEB-1 and RAEB-2 subtypes. Translocation was an independent prognostic factor for
OS and LFS in the entire patient population, as well as in subgroups of IPSS-R higher risk and
HMA-treated populations. Furthermore, in the IPSS-R higher risk group, the survival benefit
of HMAwas observedonly for patients with translocations. To the best of our knowledge, no
studies have previously reported these findings.
Table 4. Significant independent predictors of OS and LFS in IPSS-R High and Very High risk patients (n = 260).
Variables HR for OS (95% CI) p-value HR for LFS (95% CI) P-value
Translocation
No 1 1
Yes 1.72 (1.08–2.73) 0.02 1.65 (1.04–2.60) 0.03
CK
No 1 1
Yes 1.77 (1.22–2.57) < 0.01 1.48 (0.98–2.23) 0.06
HSCT
No 1 1
Yes 0.26 (0.15–0.45) < 0.01 0.23 (0.14–0.40) <0.01
Abbreviations: HR, hazard ratio; CI, confidence interval; OS, overall survival; IPSS-R, revised International Prognostic Scoring System; CK, complex
karyotype; HSCT, hematopoietic stem cell transplantation.
doi:10.1371/journal.pone.0166245.t004
Table 5. Significant independent predictors of OS and LFS in patients treated with hypomethylating agents (n = 377).
Variables HR for OS (95% CI) p-value HR for LFS (95% CI) P-value
Translocation
No 1 1
Yes 1.71 (1.04–2.82) 0.03 1.86 (1.17–2.95) <0.01
MK
No 1 -
Yes 1.68 (1.09–2.60) 0.02 - -
IPSS-R
Very High 1 1
High 0.86 (0.57–1.31) 0.49 0.67 (0.47–0.97) 0.03
Intermediate 0.54 (0.34–0.85) < 0.01 0.39 (0.27–0.58) <0.01
Low 0.22 (0.12–0.39) < 0.01 0.16 (0.10–0.27) <0.01
HSCT
No 1 1
Yes 0.43 (0.27–0.67) < 0.01 0.37 (0.24–0.57) <0.01
Abbreviations: HR, hazard ratio; CI, confidence interval; OS, overall survival; IPSS-R, revised International Prognostic Scoring System; CK, complex
karyotype; HSCT, hematopoietic stem cell transplantation.
doi:10.1371/journal.pone.0166245.t005
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MDS is cytogenetically very heterogeneous and the incidence of specific aberrations varies
considerably, with some being relatively frequent and some very rare. Chromosomal transloca-
tion has particularly low frequency, which makes establishing correlations between transloca-
tions and patient characteristics and prognoses difficult. Costa et al [7] reported that among
5,654 patients with MDS and CMML, 2,014 (36%) exhibited chromosomal abnormalities
including 213 (10%) translocations, which translates into 3.8% of the whole population. In our
cohort, the frequency of chromosomal translocations was slightly higher at 5.7% of all patients
with MDS, representing 13.7% of patients with an abnormal karyotype. Only a few studies
have addressed the prognostic impact of chromosomal translocations. Dvorak et al reported
that seven patients with t(2;11)(p21;q23) without an myeloid/lymphoid leukaemia gene rear-
rangement had a favourable prognosis with a median survival of 72 months [9]. Ai et al
reported that patients with non-t(6;9) and non-inv(3) balanced chromosomal rearrangements
exhibited short OS similar to patients with IPSS-R poor risk cytogenetics, and that SRSF2
mutation might be also be associated with worse outcome in these patients [10]. The prognos-
tic impact of chromosomal translocation as a whole, rather than for a specific translocation,
has only been evaluated by Nomdedeu et al (11). In this study of 1,653 patients with an abnor-
mal karyotype from the Spanish MDS registry, translocations were identified in 168 patients
(10.2%) [11]. Similar to our findings, translocation was associated with high BM blast at diag-
nosis (7%), RAEB-1 and RAEB-2 (49.9%), and CK (53%), as well as with a significantly shorter
survival (median OS, 1.0 year) and a higher incidence of AML transformation (21%, subhazard
ratio 1.5, P = 0.008), although translocation lost its significance in the multivariate analysis on
OS and LFS. They concluded that the poor prognosis of patients with chromosomal transloca-
tions was mainly due to a higher incidence of CK in this group. The primary difference
between the Nomdedeu et al study and the current analysis is that the former only included
patients with abnormal karyotype and included patients with CMML and other MDS/myelo-
proliferative diseases (10.7%). Here, we have shown consistent results that chromosomal trans-
location was an independent predictor of adverse outcome in the entire patient population, in
the IPSS-R high and very high risk subgroup, and in the subgroup with abnormal karyotype.
However, our conclusion needs to be verified in other datasets.
Another notable aspect in our study is that the presence of an MK was not an independent
predictor of OS and LFS. The question of whetherMK represents an independent prognostic
factor of survival has been a focus of attention with many studies devoted to the subject.MK
has been reported as a poor prognostic indicator in the whole patient population [17–20], as
well as in patients treated with HMAs [21,22]. However, Valcárcel et al reported that the prog-
nostic value of MK is the result of its strong association with a number of chromosomal abnor-
malities [23]; our study supports this finding by showing that in the context of CK, MK loses
its prognostic significance.
In randomized phase III trials, azacitidine demonstrated a survival benefit in higher-risk
patients with MDS [24] and decitabine showed superior progression-free survival compared to
best supportive care, although a survival advantage was not shown [25,26]. As there are limited
treatment options for patients who are not eligible for HSCT, HMAs represent the recom-
mended treatment for high risk patients with MDS [27]. However, whether a survival benefit
of HMAs over conventional treatments truly exists and whether IPSS-R is a useful predictor to
help guide treatment in the real world MDS population is controversial. In comparison, the OS
benefit in patients treated with azacitidine was shown via meta-analysis [28]. However, a recent
study in Taiwan reported that a better outcome with azacitidine treatment was only observed
for the IPSS-R very high risk group (median OS, 15.2 months vs. 7.5 months) [19]; addition-
ally, in another study of 821 patients with higher-riskMDS in Spain, no significant advantage
for azacitidine-treated patients was observed in terms of OS or LFS [29]. The reason for this
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difference between randomized clinical trials and population based studies is unclear; thus,
identification of the biological and clinical variables related to HMA response is of value.
Notably, the survival benefit of HMAs was only observed for patients with chromosomal
translocation in the IPSS-R high, very high risk subgroup in our study cohort. To date, only a
few studies have focused on the impact of molecularmutation on treatment response to HMAs
and these have reported contradictory results. One study found that mutation of TET2, a meth-
ylation pathway gene, was associated with an increased response to HMAs [30]. Conversely,
another study demonstrated that wild type TET2 and DNMT3Awere associated with better
progression-free survival, whereas mutation of ASXL2 (a histone-modifying gene) and wild
type SF3B1 (a splicesomal gene) was associated with better OS [31]. Due to the small number
of patients with chromosomal translocation, it is hard to draw conclusion. Nevertheless, our
findings indicate that the assessment of chromosomal translocation, not all kinds of chromo-
somal abnormalities, might help identify patients who could derive benefit fromHMA treat-
ment, and this finding should be validated in other large cohorts.
The strength of our study is that it involves a large cohort of patients from the Korea MDS
Registry and it reflects clinical daily practice. The main characteristics of the enrolled patients
including the distribution of cytogenetic risk groups and IPSS-R score are similar to those
reported in previous studies, and our study cohort should be representative of this disease. In
addition, we have assessed the impact of chromosomal translocation from various angles; i.e.,
by analysing subgroups with abnormal karyotype, CK, and IPSS-R poor and very poor
cytogenetics.
In summary, we demonstrated the clinical significance of chromosomal translocation in
MDS. Chromosomal translocation is an independent predictor of adverse outcome and has an
additional prognostic value in discriminating patients with MDS and higher risk IPSS-R who
might benefit fromHMA treatment. Further studies in other populations are needed to vali-
date the clinical relevance of translocation in patients with MDS.
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